BioSpace News Archive

Cytokinetics, Incorporated announced that on September 30, 2021 it granted stock options to purchase an aggregate of 206,300 shares of common stock to 14 new employees, whose employment commenced in September 2021, as a material inducement to their employment.

X4 Pharmaceuticals, Inc. announced that, on September 30, 2021, the Compensation Committee of X4’s Board of Directors issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.

Prothena Corporation plc, a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, announced that Chief Financial Officer Tran B. Nguyen has been appointed to the additional and newly created role of Chief Strategy Officer.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), today announced new long-term data from the OPTIC clinical trial of ADVM-022 single, in-office intravitreal (IVT) injection gene therapy in patients requiring frequent anti-VEGF injections for their neovascular or wet age-related macular degeneration (wet AMD).

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 147,300 shares of Karyopharm’s common stock to 21 newly-hired employees, with a grant date of September 30, 2021.

Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 17 newly-hired employees options to purchase an aggregate of 180,000 shares of Akebia’s common stock on September 30, 2021, as inducements material to each such employee’s entering into employment with Akebia.

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, reported that, in connection with the appointment of Erik Atkisson as Eiger’s General Counsel and Chief Compliance Officer, the company granted him a stock option to purchase 180,000 shares of Eiger’s common stock.

CTI BioPharma Corp. (Nasdaq: CTIC) today announced topline results from the PRE-VENT trial (NCT04404361) of pacritinib in hospitalized patients with severe COVID-19. PRE-VENT, a randomized, double-blind, placebo-controlled multicenter study, compared pacritinib/standard of care versus placebo/standard of care in hospitalized patients with severe COVID-19, including patients with and without cancer.

Xeris Pharmaceuticals, Inc. announced that on October 1, 2021, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggregate of 28,750 shares of its common stock to 20 new employee under Xeris’ Inducement Equity Plan.

MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced the grant of inducement stock options for an aggregate of 136,000 shares of the company’s common stock to three new employees.